A Phase 3 interventional study of Danicamtiv in Symptomatic Genetic Dilated Cardiomyopathy (DCM), sponsored by Kardigan, Inc.. Recruiting at 78 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by Kardigan, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 64 studies in Cardiomyopathy, Dilated with a site in United States — 14 open to participants now, 20 under way, 2 of them phase 3. Cardiomyopathy, Dilated · United States.
Among the 64 studies in Cardiomyopathy, Dilated with a site in United States, this one is the 3rd largest by planned enrollment of the 42 interventional ones that give a count, is one of 5 that started in 2026, is one of 4 in phase 3, reaches primary completion later than 19 of the 19 other live ones, and was the 64th registered.
255 studies on the registry are indexed under Cardiomyopathy, Dilated; 66 are open to participants now.
Browse Cardiomyopathy, Dilated studies →14 of the 64 studies in Cardiomyopathy, Dilated with a site in United States are open now. Recruiting first, the newest first:
Affinia Therapeutics · Sites in United States, Canada
Ages 18–70
Nuevocor Pte. Ltd. · Sites in United States
Ages 18+
Rocket Pharmaceuticals Inc. · Sites in United States
Ages 18–65
Kardigan, Inc. · Sites in United States, Belgium, Denmark and 8 more countries
Ages 18+
Prolaio · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 53 Cardiomyopathy, Dilated studies recruiting now, 30 (57%) set no upper age limit and 15 (28%) stop at 75 or younger; 13 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
64 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 17 · Phase 3 5 · Phase 4 2
First in 1992; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 332 is above the median of 43 across 145 interventional studies indexed under Cardiomyopathy, Dilated.
Median enrollment 37 across the 42 interventional studies, 166 across the 20 observational. Of the 38 that completed or were terminated, 16 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 64 have an industry lead sponsor. The 10 most frequent:
Kardigan, Inc. is the lead sponsor of 5 studies on the registry; 4 are open to participants now.
Kardigan, Inc. has 2 studies filed under Cardiomyopathy, Dilated — fewer than ten, so there is no comparison to draw.
7 of the studies in Cardiomyopathy, Dilated with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07210723Phase 3Kardigan, Inc.A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy | 2027-09 |
| NCT04638621Ohio State UniversityDilated Cardiomyopathy-Cardiac Magnetic Resonance (DCM-CMR) Ancillary Study | 2026-12 |
| NCT06688396Lancaster General HospitalDilated Cardiomyopathy Detection Using AI and Screening With Mobile Technology (DCM-DETECT) | 2026-12 |
| NCT04476901Joshua M HareAdministration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy | 2027-04 |
| NCT06464588Emory UniversityA Phase 1 Open-Label Study of the Safety of Intravenous Allogeneic Neonatal Mesenchymal Cells (nMSCs) in Young Adult (1A) and Pediatric (1B) Patients With Dilated Cardiomyopathy (DCM) | 2027-07 |
Add all 7 to your calendar (.ics) → With an account.
Among the 64 studies in Cardiomyopathy, Dilated with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Danicamtiv is an investigational medication, which means it is still being studied and has not been approved. The purpose of this study is to learn how well danicamtiv works, how safe it is, how well people can take it when used in patients with genetic or familial dilated cardiomyopathy (DCM). There are currently no approved medicines made specifically to treat genetic or familial DCM.
The Sponsor is studying an investigational medication called danicamtiv to understand its long-term benefits and risks in patients with symptomatic genetic or familial DCM. This study will examine the durability of treatment effects with continued exposure and evaluate appropriateness of chronic dosing over time.
Participants will:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Danicamtiv
Danicamtiv will be administered twice daily for up to 5 years
Frequency and severity of treatment-emergent adverse events (TEAEs)
Time frame: 61 months
Frequency and severity of adverse events of special interest (AESIs)
Time frame: 61 months
Frequency and severity of serious adverse events (SAEs)
Time frame: 61 months
Frequency and severity of disease-related events (DREs)
Time frame: 61 months
Frequency of abnormal findings from physical examination
Time frame: 61 months
Frequency of abnormal findings from vital signs
Time frame: 61 months
Frequency of abnormal findings from 12-lead electrocardiograms (ECGs)
Time frame: 61 months
Frequency of abnormal findings from clinical laboratory assessments
Time frame: 61 months
Change from Baseline (Day 1) to Week 26, Months 18, 30, 42, 54, 60, and 61 in cardiac structure, function, and size using Transthoracic Echocardiogram (TTE)
Including but not limited to left atrial function index (LAFI), left atrial volume index (LAVI), maximum left atrial volume index (LAmaxVi), minimum left atrial volume index (LAminVi), left atrial emptying fraction (LAEF), left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVEDD), left ventricular end diastolic volume (LVEDV), left ventricular end systolic volume (LVESV), early diastolic mitral inflow velocity/early diastolic mitral annular tissue velocity (E/e'), left ventricular global longitudinal strain (LVGLS), left ventricular global circumferential strain (LVGCS), and left ventricular mass index (LVMI)
Time frame: 61 months
Change from Baseline (Day 1) to Week 26, Months 12, 18, 24, 30, 36, 42, 48, 54, 60, and 61 in Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-23 CSS)
All scores are represented on a 0-to-100-point scale, where lower scores represent more severe symptoms and/or limitations and scores of 100 indicate no symptoms, no limitations, and excellent quality of life.
Time frame: 61 months
Change from Baseline (Day 1) to Week 26, Months 12, 18, 24, 30, 36, 42, 48, 54, 60, and 61 in EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) Utility Score
Time frame: 61 months
Change from Baseline (Day 1) to Week 26, Months 12, 18, 24, 30, 36, 42, 48, 54, 60, and 61 in EuroQol Visual Analogue Scale (EQ-VAS) Score
Time frame: 61 months
Proportion of participants from Baseline (Day 1) to Week 26, Months 12, 18, 24, 30, 36, 42, 48, 54, 60, and 61 who achieve at least a one-class improvement in New York Heart Association (NYHA) class
NYHA is a system used to categorize the severity of heart failure symptoms based on a patient's functional capacity, where 1 indicates no symptoms or limitations and 4 indicates symptoms present at rest.
Time frame: 61 months
Change from Baseline (Day 1) to Week 26, Months 12, 18, 24, 30, 36, 42, 48, 54, 60, and 61 in N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentrations
Time frame: 61 months
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2026 (actual). Primary completion is estimated for Nov 2032, 75 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Danicamtiv
Kardigan, Inc.